{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:22:18Z","timestamp":1780924938984,"version":"3.54.1"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105272","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:24:07Z","timestamp":1773246247000},"page":"105272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Multidisciplinary therapy managements in endometrial and renal cancer patients treated with pembrolizumab and lenvatinib: a virtuous circle between oncologists and organ specialists"],"prefix":"10.1016","volume":"222","author":[{"given":"Roberto","family":"Sabbatini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cosmai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Ianiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spallarossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Vacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105272_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/725410","article-title":"Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment","volume":"2013","author":"Ahmadieh","year":"2013","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.critrevonc.2026.105272_bib2","unstructured":"American Cancer Society, 2025. Uterine Cancer Survival Rate | Survival Rates for Endometrial Cancer."},{"key":"10.1016\/j.critrevonc.2026.105272_bib3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105272_bib4","article-title":"The use of faecal microbiota transplantation (FMT) in Europe: a Europe-wide survey","volume":"9","author":"Baunwall","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.critrevonc.2026.105272_bib5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ando.2018.07.011","article-title":"Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors","volume":"79","author":"Buffier","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib6","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.40627","article-title":"Immune checkpoint inhibitor-induced colitis: how long does the threat last?","author":"Calle Sarmiento","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.critrevonc.2026.105272_bib7","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/life12081149","article-title":"Immune-checkpoint-inhibitor-related lung toxicity: a multicentre real-life retrospective portrait from six Italian centres","volume":"12","author":"Cameli","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.critrevonc.2026.105272_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejim.2022.07.005","article-title":"Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors","volume":"103","author":"Campochiaro","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.critrevonc.2026.105272_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ando.2018.07.005","article-title":"Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions","volume":"79","author":"Castinetti","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.tem.2021.10.009","article-title":"The changing clinical spectrum of endocrine adverse events in cancer immunotherapy","volume":"33","author":"Chiloiro","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2026.105272_bib11","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/jc.2018-01836","article-title":"Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy","volume":"104","author":"Colombo","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2026.105272_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/oncolo\/oyad201","article-title":"Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab","volume":"29","author":"Colombo","year":"2024","journal-title":"The Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105272_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105272_bib14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ckj\/sfaa127","article-title":"Preventive strategies for acute kidney injury in cancer patients","volume":"14","author":"Cosmai","year":"2021","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.critrevonc.2026.105272_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000618","article-title":"Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies","volume":"5","author":"Cosmai","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105272_bib16","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105272_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.41949","article-title":"Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer","volume":"74","author":"Cunningham-Bussel","year":"2022","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.critrevonc.2026.105272_bib18","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41585-023-00776-5","article-title":"Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC","volume":"20","author":"Das","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti\u2013PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105272_bib20","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1148\/radiol.2019192094","article-title":"Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American college of radiology and the national kidney foundation","volume":"294","author":"Davenport","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.critrevonc.2026.105272_bib21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ando.2023.03.009","article-title":"Endocrine-related adverse conditions induced by tyrosine kinase inhibitors","volume":"84","author":"De Leo","year":"2023","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib22","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0012-2019","article-title":"Management of pulmonary toxicity associated with immune checkpoint inhibitors","volume":"28","author":"Delaunay","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.critrevonc.2026.105272_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ando.2018.07.003","article-title":"Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors","volume":"79","author":"Drui","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib24","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib25","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105272_bib26","unstructured":"European Medicines Agency, 2025a. Keytruda - Summary of Product Characteristics."},{"key":"10.1016\/j.critrevonc.2026.105272_bib27","unstructured":"European Medicines Agency, 2025b. Lenvima - Summary of Product Characteristics."},{"key":"10.1016\/j.critrevonc.2026.105272_bib28","unstructured":"European Medicines Agency, 2025c. Kisplyx - Summary of Product Characteristics."},{"key":"10.1016\/j.critrevonc.2026.105272_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1679\/aohc.61.17","article-title":"Immunohistochemical Localization of Vascular Endothelial Growth Factor in the Endocrine Glands of the Rat","volume":"61","author":"Fan","year":"1998","journal-title":"Arch. Histol. Cytol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101966","article-title":"Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs","volume":"84","author":"Fogli","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105272_bib31","unstructured":"Food and Drug Administration, 2022. Commissioner O of the FDA Approves First Fecal Microbiota Product."},{"key":"10.1016\/j.critrevonc.2026.105272_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yjmcc.2019.11.058","article-title":"Anti-tumor drug lenvatinib induced cardiotoxicity via mitochondrial oxidative stress and apoptosis","volume":"140","author":"Gao","year":"2020","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib33","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.clgc.2023.12.010","article-title":"Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma","volume":"22","author":"Gr\u00fcnwald","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105272_bib34","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ijc.35288","article-title":"Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial","volume":"156","author":"Gr\u00fcnwald","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105272_bib35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2021.01.036","article-title":"Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990\u20132019","volume":"161","author":"Gu","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib36","article-title":"Pulmonary complications of tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with non-small cell lung cancer","volume":"28","author":"Gupta","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105272_bib37","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib39","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib40","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1038\/s41467-020-18127-y","article-title":"Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma","volume":"11","author":"Ianiro","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105272_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2019.05.015","article-title":"Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders","volume":"141","author":"Jannin","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105272_bib43","article-title":"Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study","volume":"15","author":"Kataoka","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105272_bib44","doi-asserted-by":"crossref","first-page":"43676","DOI":"10.1038\/s41598-025-27578-6","article-title":"Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study","volume":"15","author":"Kato","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105272_bib45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.critrevonc.2026.105272_bib46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer\u2014clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.critrevonc.2026.105272_bib47","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.3390\/cancers14184369","article-title":"Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma","volume":"14","author":"Leucht","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105272_bib48","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/01.HYP.0000215283.53943.39","article-title":"Microvascular Plasticity and Experimental Heart Failure","volume":"47","author":"L\u00e9vy","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.critrevonc.2026.105272_bib49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2023.03.015","article-title":"Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician\u2019s Choice","volume":"186","author":"Lorusso","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105272_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.979519","article-title":"Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma","volume":"12","author":"Lorusso","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105829","article-title":"Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer","volume":"174","author":"Lu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.critrevonc.2026.105272_bib52","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.critrevonc.2026.105272_bib53","doi-asserted-by":"crossref","first-page":"84579","DOI":"10.18632\/oncotarget.19961","article-title":"Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials","volume":"8","author":"MacKay","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105272_bib54","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1161\/HYPERTENSIONAHA.120.16454","article-title":"Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition\u2013Induced Hypertension: The HYPAZ Trial","volume":"77","author":"M\u00e4ki-Pet\u00e4j\u00e4","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.critrevonc.2026.105272_bib55","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105272_bib56","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib57","doi-asserted-by":"crossref","first-page":"S699","DOI":"10.1016\/j.annonc.2025.08.1756","article-title":"1119P Lenvatinib plus pembrolizumab (L + P) vs treatment of physician\u2019s choice (TPC) for advanced endometrial cancer (EC): 5-year outcomes from study 309\/KEYNOTE-775","volume":"36","author":"Makker","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib58","doi-asserted-by":"crossref","first-page":"e1599","DOI":"10.1002\/onco.13883","article-title":"Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab","volume":"26","author":"Makker","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105272_bib59","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J. Hypertens."},{"key":"10.1016\/j.critrevonc.2026.105272_bib60","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105272_bib61","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib62","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105272_bib63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs\u2014Part A: Renal, Penile, and Testicular Tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib64","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study","volume":"42","author":"Motzer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib65","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.clgc.2023.12.007","article-title":"Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events","volume":"22","author":"Nizam","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105272_bib66","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR\u2013TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non\u2013Small Cell Lung Cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib67","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.3390\/ijerph20064926","article-title":"Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists","volume":"20","author":"Pacholczak-Madej","year":"2023","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"10.1016\/j.critrevonc.2026.105272_bib68","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor\u2013Associated Hypertension and Vascular Disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.critrevonc.2026.105272_bib69","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s13256-021-02926-y","article-title":"Patterns of immunotherapy-induced pneumonitis in patients with non-small-cell lung cancer: a case series","volume":"15","author":"Picard","year":"2021","journal-title":"J. Med. Case Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105272_bib70","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nrneph.2015.15","article-title":"Renal effects of targeted anticancer therapies","volume":"11","author":"Porta","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.critrevonc.2026.105272_bib71","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib72","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.critrevonc.2026.105272_bib73","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/annrheumdis-2019-eular.2870","article-title":"THU0649 Phenotypic clusters of rheumatic\/systemic immune-related adverse events induced by cancer immunotherapies (immunocancer international registry)","volume":"78","author":"Ramos-Casals","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.critrevonc.2026.105272_bib74","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib75","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105272_bib76","unstructured":"SEER, 2021. Cancer of the Endometrium - Cancer Stat Facts."},{"key":"10.1016\/j.critrevonc.2026.105272_bib77","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105272_bib78","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-Induced Interstitial Lung Disease: A Systematic Review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2026.105272_bib79","doi-asserted-by":"crossref","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","article-title":"Immune checkpoint inhibitor-induced colitis: A comprehensive review","volume":"7","author":"Som","year":"2019","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.critrevonc.2026.105272_bib80","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/AOG.0000000000005321","article-title":"Trends in Uterine Cancer Mortality in the United States: A 50-Year Population-Based Analysis","volume":"142","author":"Somasegar","year":"2023","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib81","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib82","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury","volume":"18","author":"Sprangers","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib83","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies\u2013focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.critrevonc.2026.105272_bib84","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00345-012-1001-3","article-title":"Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis","volume":"31","author":"Tsao","year":"2013","journal-title":"World J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib85","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000521979","article-title":"Use of pembrolizumab in end-stage renal disease: a case report with complete response","volume":"15","author":"Vitorino","year":"2022","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105272_bib86","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105272_bib87","article-title":"Treatment strategies for clear cell renal cell carcinoma: past, present and future","volume":"13","author":"Yang","year":"2023","journal-title":"Front. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:43:06Z","timestamp":1778481786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":87,"alternative-id":["S1040842826001599"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105272","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidisciplinary therapy managements in endometrial and renal cancer patients treated with pembrolizumab and lenvatinib: a virtuous circle between oncologists and organ specialists","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105272"}}